KURA vs MGNX

For growth investors, Kura Oncology, Inc.

(KURA) is the stronger pick with 25. 2% revenue growth year-over-year, versus 0. 8% for MacroGenics, Inc. (MGNX). Analysts rate Kura Oncology, Inc. (KURA) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Kura Oncology, Inc.

(KURA) delivered a total return of -61. 8%, compared to -90. 6% for MacroGenics, Inc. (MGNX). Over 10 years, the gap is even starker: KURA returned +245. 8% versus MGNX's -83. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Kura Oncology, Inc.

(KURA) is the lower-risk stock at 1. 66β versus MacroGenics, Inc. 's 1. 93β — meaning MGNX is approximately 16% more volatile than KURA relative to the S&P 500. On balance sheet safety, Kura Oncology, Inc. (KURA) carries a lower debt/equity ratio of 6% versus 66% for MacroGenics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Kura Oncology, Inc.

(KURA) is pulling ahead at 25. 2% versus 0. 8% for MacroGenics, Inc. (MGNX). On earnings-per-share growth, the picture is similar: MacroGenics, Inc. grew EPS -10. 3% year-over-year, compared to -57. 4% for Kura Oncology, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

MacroGenics, Inc.

(MGNX) is the more profitable company, earning -49. 9% net margin versus -412. 9% for Kura Oncology, Inc. — meaning it keeps -49. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MGNX leads at -48. 7% versus -449. 9% for KURA. At the gross margin level — before operating expenses — KURA leads at 99. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Kura Oncology, Inc.

(KURA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+245. 8% 10Y return). MacroGenics, Inc. (MGNX) carries a higher beta of 1. 93 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KURA: +245. 8%, MGNX: -83. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KURA is a small-cap high-growth stock; MGNX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.